...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Lack of communication
4
Sep 05, 2017 04:31PM

Hi Toinv,

i am also very frustrated with the lack of information or communication given on the Zen3694 trial, however I believe that there was a very sick surviving patient on the trial after 6 months on the  drug that was still alive . That being the case that can't be a bad thing. We wait to hear what progress is happening with the trial 

 

Share
New Message
Please login to post a reply